Shell effects on acoustic performance of a drug‐delivery system activated by ultrasound
Source abstract
Abstract
Abstract The composition of microcapsules designed for drug delivery significantly impacts their properties. Ultrasound contrast agents, consisting of stabilized microbubbles (MBs), have emerged as versatile potential drug delivery vehicles to both image and overcome challenges associated with systemic chemotherapy. In our development of polylactic acid MBs decorated with immune‐shielding polyethylene glycol chains, we have shown that the balance between acoustic behavior and immune avoidance was scalable and amenable to two distinct PEGylation methods, either incorporation of 5 wt% PEGylated PLA or insertion of 1 wt% PEGylated lipid (LipidPEG) in the polymeric shell. Here we describe the effects of shell compositions on MB functionalization for use in targeted cancer therapy. We chose tumor necrosis factor‐related apoptosis inducing ligand (TRAIL) as the targeting ligand, motivated by the ability to both target cells and selectively induce tumor cell death upon binding. Additionally, the MBs were designed to co‐encapsulate the chemotherapeutic doxorubicin (Dox) within the shell that works with TRAIL to sensitize resistant cells. We have previously shown that the MBs shatter in response to ultrasound focused at the tumor site, delivering drug‐eluting fragments. This study demonstrates the effect of shell characteristics and MB functionalization (TRAIL‐ligated and Dox‐loaded MBs) on the acoustic response of MBs, and the cumulative effect of shell type. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 3189–3196, 2017.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Ultrasound and Hyperthermia Applications · Photoacoustic and Ultrasonic Imaging · Ultrasound and Cavitation Phenomena
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Biomedical Engineering Science, and Health Systems, Drexel University Philadelphia Pennsylvania 19104
Department of Radiology Thomas Jefferson University Philadelphia Pennsylvania 19107
Funding
Society of Interventional Radiology · W. W. Smith Charitable Trust
References (41)
Show source-provided references
1. Cancer F. · 2017
2. 10.3322/caac.2138710.3322/caac.21387 ↗
3. 10.1038/nrc326110.1038/nrc3261 ↗
4. 10.1016/j.ijpharm.2011.05.03010.1016/j.ijpharm.2011.05.030 ↗
5. 10.1016/j.jconrel.2009.12.02110.1016/j.jconrel.2009.12.021 ↗
6. 10.1016/j.biomaterials.2016.06.03610.1016/j.biomaterials.2016.06.036 ↗
7. 10.1021/acs.langmuir.5b0347310.1021/acs.langmuir.5b03473 ↗
8. 10.1177/153537021557916710.1177/1535370215579167 ↗
9. 10.1038/550510.1038/5505 ↗
10. 10.1182/blood.V98.3.79510.1182/blood.V98.3.795 ↗
11. 10.1038/sj.onc.120723210.1038/sj.onc.1207232 ↗
12. 10.1016/j.acra.2011.06.01310.1016/j.acra.2011.06.013 ↗
13. 10.1016/j.ultras.2009.03.00310.1016/j.ultras.2009.03.003 ↗
14. Doxorubicin loaded contrast agents for ultrasound triggered drug delivery: importance of process parameters
15. 10.1109/TBME.2009.203049710.1109/TBME.2009.2030497 ↗
16. 10.1016/j.drup.2008.02.00110.1016/j.drup.2008.02.001 ↗
17. 10.1016/j.ygyno.2004.04.01210.1016/j.ygyno.2004.04.012 ↗
18. 10.1038/sj.cgt.770079210.1038/sj.cgt.7700792 ↗
19. 10.1006/gyno.2001.619410.1006/gyno.2001.6194 ↗
20. 10.1158/0008-5472.CAN-04-370110.1158/0008-5472.CAN-04-3701 ↗
21. 10.1002/jbm.a.1058610.1002/jbm.a.10586 ↗
22. 10.1016/j.biomaterials.2007.05.04410.1016/j.biomaterials.2007.05.044 ↗
23. 10.1002/bit.2267810.1002/bit.22678 ↗
24. Oum K. · 200810.17918/etd-3469 ↗
25. 10.1002/jbm.a.3418910.1002/jbm.a.34189 ↗
26. 10.1016/j.ultras.2006.04.00310.1016/j.ultras.2006.04.003 ↗
27. 10.1016/S0041-624X(99)00148-110.1016/S0041-624X(99)00148-1 ↗
28. 10.2174/13816121280009995510.2174/138161212800099955 ↗
29. 10.1007/s11517-009-0497-110.1007/s11517-009-0497-1 ↗
30. 10.1016/0041-624X(92)90041-J10.1016/0041-624X(92)90041-J ↗
31. Morse PM · 1968
32. 10.1121/1.150942810.1121/1.1509428 ↗
33. 10.1016/j.jconrel.2005.11.00610.1016/j.jconrel.2005.11.006 ↗
34. 10.1016/0169-409X(95)00026-410.1016/0169-409X(95)00026-4 ↗
35. 10.1016/S0927-7765(99)00156-310.1016/S0927-7765(99)00156-3 ↗
36. 10.1073/pnas.88.24.1146010.1073/pnas.88.24.11460 ↗
37. 10.1016/j.jconrel.2012.08.01410.1016/j.jconrel.2012.08.014 ↗
38. 10.1016/j.jconrel.2005.06.01510.1016/j.jconrel.2005.06.015 ↗
39. 10.1016/j.polymdegradstab.2005.01.06010.1016/j.polymdegradstab.2005.01.060 ↗
40. 10.1016/j.biomaterials.2014.04.02610.1016/j.biomaterials.2014.04.026 ↗
41. 10.1063/1.356506210.1063/1.3565062 ↗